According to the study, the global auto-injectors market is likely to grow significantly during the forecast period, due to increasing
prevalence of anaphylaxis, increasing cases with multiple sclerosis, rising
geriatric population and high production of biologics. Additionally, increasing
healthcare spending and various beneficial features of auto-injectors also
contribute to the growth of the overall market. However, high cost of
auto-injectors and stringent regulatory requirements are some of the key
factors restraining the growth of global auto-injectors market.
Explore Report Description at: https://www.psmarketresearch.com/market-analysis/auto-injectors-market
As per the findings of the research, the prefilled auto-injectors is the larger product category in the global auto-injectors market, primarily due to increasing availability of user friendly prefilled auto-injectors in disposable form. Based on manufacturing design, standardized auto-injector was the larger contributor to the global auto-injectors market in comparison to customized auto-injector in 2016. Anaphylaxis was the largest application for auto-injectors, followed by multiple sclerosis, rheumatoid arthritis and other diseases, in 2016. According to World Allergy Organization (WAO), the prevalence of anaphylaxis ranged from 2% of the population in the US, to 0.1% of the population in Korea, and 0.6% to 1% of the population in Australia.
Most
of the biologics, such as monoclonal antibodies, anticoagulants, and vaccines
are large molecules which need to be administered parenterally to achieve the
desired therapeutic effects. The demand for development of injectable biologic
therapies is increasing, since many peptides break down too quickly in the
stomach and after which they no longer remain useful for treatment. Also,
various biologic drugs and vaccines require to be injected directly into the
bloodstream. The introduction of biosimilars would enforce the usage of
injectable in auto-injectors, and thus the consumption and demand of auto-injectors
is expected to increase.
Explore Report Description at: https://www.psmarketresearch.com/market-analysis/auto-injectors-market
As per the findings of the research, the prefilled auto-injectors is the larger product category in the global auto-injectors market, primarily due to increasing availability of user friendly prefilled auto-injectors in disposable form. Based on manufacturing design, standardized auto-injector was the larger contributor to the global auto-injectors market in comparison to customized auto-injector in 2016. Anaphylaxis was the largest application for auto-injectors, followed by multiple sclerosis, rheumatoid arthritis and other diseases, in 2016. According to World Allergy Organization (WAO), the prevalence of anaphylaxis ranged from 2% of the population in the US, to 0.1% of the population in Korea, and 0.6% to 1% of the population in Australia.
Globally,
the increasing demand for biologics has been playing a key role in the growth
of the auto-injectors market. The rapidly increasing burden of anaphylaxis,
multiple sclerosis, rheumatoid arthritis and other diseases further compels
government organizations and healthcare providers to provide improved
facilities for effective disease treatment, leading to rising number of
launches of technologically advanced products, globally.
Explore
Report Sample at: https://www.psmarketresearch.com/market-analysis/auto-injectors-market/report-sample
Some
of the key players operating in the global auto-injectors market include Mylan
N.V., Antares Pharma Inc., Becton, Dickinson & Co., Eli Lilly and Company, Pfizer,
Inc., Bayer AG, Novartis International AG, Bristol-Myer Squibb,
Novartis AG, Amgen Inc. and Biogen Inc.
No comments:
Post a Comment